Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1988]

Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients

Professor Meletios Dimopoulos - University of Athens, Greece

$Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients ( Professor Meletios Dimopoulos - University of Athens, Greece )$

MLN9708 in combination with lenalidomide and dexamethasone

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

MLN9708 in combination with lenalidomide and dexamethasone ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

History of epidermal stem cell use in the clinical setting

Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy

History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )

Exercise benefit to lifespan may be due to stem cell increase

Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of...

Exercise benefit to lifespan may be due to stem cell increase ( Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA )

Diagnosis of blood cancer after a breast cancer diagnosis

Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA

Diagnosis of blood cancer after a breast cancer diagnosis ( Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA )

Histone deacetylases targeted as new strategy against graft versus host disease

Prof Sung Choi - University of Michigan, Ann Arbor, USA

Histone deacetylases targeted as new strategy against graft versus host disease ( Prof Sung Choi - University of Michigan, Ann Arbor, USA )

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic...

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston...

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab ( Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA )

Uncovering new targets for treatment of chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus...

Uncovering new targets for treatment of chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA )

Targeting the proteasome mechanism

Dr Stig Linder – Karolinska Institute, Stockholm, Sweden

Targeting the proteasome mechanism ( Dr Stig Linder – Karolinska Institute, Stockholm, Sweden )

Effect of hypoxia on cancer progression and adaptive response

Dr Greg Semenza – John Hopkins, Baltimore, USA

Effect of hypoxia on cancer progression and adaptive response ( Dr Greg Semenza – John Hopkins, Baltimore, USA )

More from ecancer